A study by the Boston Consulting Group shows that drug candidate molecules discovered through AI have been 80-90% successful in Phase I clinical trials.

According to the study, molecules discovered using AI were significantly more successful in the early phases of experiments compared to the pharmaceutical industry average. This could lead to an increase in the number of successful drugs. AI has the potential to double the effectiveness of pharmaceutical research and development, contributing to the discovery of more drugs and vaccines.